AR050615A1 - Composiciones farmaceuticas para la administracion oral - Google Patents

Composiciones farmaceuticas para la administracion oral

Info

Publication number
AR050615A1
AR050615A1 ARP050103558A ARP050103558A AR050615A1 AR 050615 A1 AR050615 A1 AR 050615A1 AR P050103558 A ARP050103558 A AR P050103558A AR P050103558 A ARP050103558 A AR P050103558A AR 050615 A1 AR050615 A1 AR 050615A1
Authority
AR
Argentina
Prior art keywords
granules
therapeutic compound
moisture sensitive
mixture
fusion
Prior art date
Application number
ARP050103558A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR050615A1 publication Critical patent/AR050615A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP050103558A 2004-08-27 2005-08-25 Composiciones farmaceuticas para la administracion oral AR050615A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60532704P 2004-08-27 2004-08-27
US61682804P 2004-10-07 2004-10-07

Publications (1)

Publication Number Publication Date
AR050615A1 true AR050615A1 (es) 2006-11-08

Family

ID=35447883

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103558A AR050615A1 (es) 2004-08-27 2005-08-25 Composiciones farmaceuticas para la administracion oral

Country Status (21)

Country Link
US (1) US20080050443A1 (https=)
EP (2) EP3087975A1 (https=)
JP (1) JP5147399B2 (https=)
KR (8) KR20220061249A (https=)
CN (1) CN101010068B (https=)
AR (1) AR050615A1 (https=)
AU (1) AU2005276583B2 (https=)
BR (1) BRPI0514682B8 (https=)
CA (1) CA2575499A1 (https=)
DK (1) DK1786401T3 (https=)
ES (1) ES2647671T3 (https=)
HU (1) HUE034653T2 (https=)
MX (1) MX2007002253A (https=)
MY (1) MY144297A (https=)
PE (1) PE20060652A1 (https=)
PL (1) PL1786401T3 (https=)
PT (1) PT1786401T (https=)
RU (1) RU2383332C2 (https=)
SI (1) SI1786401T1 (https=)
TW (1) TWI402082B (https=)
WO (1) WO2006021455A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766487C2 (ru) 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
AU2005210285B2 (en) 2004-02-05 2008-01-24 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
EP1995237A4 (en) 2006-03-08 2011-07-06 Kyorin Seiyaku Kk PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF
WO2007128801A1 (en) * 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
WO2008114857A1 (ja) 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
WO2010016584A1 (ja) * 2008-08-07 2010-02-11 杏林製薬株式会社 ビシクロ[２．２．２]オクチルアミン誘導体の製造方法
KR20110044780A (ko) * 2008-08-14 2011-04-29 교린 세이야꾸 가부시키 가이샤 안정화된 의약 조성물
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CN102438617A (zh) 2009-03-27 2012-05-02 杏林制药株式会社 含有碱性添加剂的基质型缓释制剂
JP2011057586A (ja) * 2009-09-08 2011-03-24 Kyorin Pharmaceutical Co Ltd ｐＨ非依存性マトリックス型徐放性製剤
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US8989577B2 (en) 2012-06-21 2015-03-24 Qualcomm Incorporated Methods and systems for implementing time-division duplexing in the physical layer
US9071358B2 (en) 2012-06-21 2015-06-30 Qualcomm Incrorporated Repeater fiber-coax units
US9363017B2 (en) 2012-07-06 2016-06-07 Qualcomm Incorporated Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
PL3512505T3 (pl) 2016-09-16 2023-08-07 Galenicum Health S.L.U. Farmaceutyczne kompozycje wildagliptyny
CN117695279A (zh) * 2023-11-28 2024-03-15 九华华源药业(桂林)有限公司 氯雷他定组合物及氯雷他定药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
PT654263E (pt) 1993-11-23 2002-06-28 Euro Celtique Sa Metodo para a preparacao de uma composicao de libertyacao prolongada
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US20020142037A1 (en) 1996-10-01 2002-10-03 Nabil Farah Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix
WO1998018763A1 (en) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CA2302275C (en) * 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
CA2502269C (en) 2002-10-18 2009-12-22 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral

Also Published As

Publication number Publication date
CN101010068B (zh) 2013-05-22
RU2383332C2 (ru) 2010-03-10
RU2007110953A (ru) 2008-10-10
KR20130043697A (ko) 2013-04-30
WO2006021455A1 (en) 2006-03-02
MY144297A (en) 2011-08-29
KR20200087870A (ko) 2020-07-21
BRPI0514682A (pt) 2008-06-17
KR20220061249A (ko) 2022-05-12
KR101613775B1 (ko) 2016-04-19
KR20070049646A (ko) 2007-05-11
TWI402082B (zh) 2013-07-21
PE20060652A1 (es) 2006-08-11
BRPI0514682B8 (pt) 2021-05-25
KR20170103039A (ko) 2017-09-12
KR20190006612A (ko) 2019-01-18
EP1786401A1 (en) 2007-05-23
US20080050443A1 (en) 2008-02-28
JP5147399B2 (ja) 2013-02-20
CN101010068A (zh) 2007-08-01
JP2008510764A (ja) 2008-04-10
MX2007002253A (es) 2007-04-20
SI1786401T1 (sl) 2017-12-29
BRPI0514682B1 (pt) 2019-06-04
DK1786401T3 (da) 2017-11-27
KR20160017123A (ko) 2016-02-15
CA2575499A1 (en) 2006-03-02
EP3087975A1 (en) 2016-11-02
EP1786401B1 (en) 2017-08-16
ES2647671T3 (es) 2017-12-26
HUE034653T2 (hu) 2018-02-28
PL1786401T3 (pl) 2018-01-31
PT1786401T (pt) 2017-11-22
TW200613005A (en) 2006-05-01
KR20160136465A (ko) 2016-11-29
AU2005276583A1 (en) 2006-03-02
AU2005276583B2 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
AR050615A1 (es) Composiciones farmaceuticas para la administracion oral
PH12022553603A1 (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
ES2606043T3 (es) Derivados de biarilo como moduladores de nAChR
ES2452868T3 (es) Nuevos inhibidores de desacetilasas de histonas basados simultáneamente en 1H-pirroles trisustituidos y en espaciadores aromáticos y heteroaromáticos
AR020727A1 (es) Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
HRP20230052T1 (hr) Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
SA112330689B1 (ar) صيغة كبسولات تشتمل على مونتليوكاست وليڤوستيريزين
CN110664816A (zh) Seca抑制剂以及其制备和使用方法
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
CN112566898B (zh) 12(s)-脂氧合酶（12-lox）的选择性抑制剂及其使用方法
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
JP6168673B2 (ja) アリールアルキルアミン化合物含有医薬組成物
FI3769765T3 (fi) Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
ES2235383T3 (es) Beta-alaninas sustituidas.
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
ES2989870T3 (es) Composición farmacéutica
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
HRP20220234T1 (hr) Kristalni oblici
CL2004000779A1 (es) Compuestos derivados de 3-azabiciclo [3.2.1]octano, composicion farmaceutica, procedimiento de preparacion, util para preparar medicamentos para tratar sindrome de intestino irritable, estrenimiento, nauseas, vomitos, disfuncion sexual, alzheimer, en
CO6280494A2 (es) Composiciones que comprenden euphorbia prostrata y procesos de preparacion de las mismas

Legal Events

Date Code Title Description
FC Refusal